
    
      The objectives of this clinical trial are to evaluate: 1) the safety of multiple biweekly
      (i.e. every other week) intravenous (IV) doses of Replagal over 26 weeks in 25 children ages
      7-17 years old with Fabry Disease, and 2) the pharmacokinetics of Replagal in this patient
      population. Safety will be determined by standard clinical and laboratory measurements.
    
  